Detection of tumour DNA in serum of colorectal cancer patients
Detection of tumour DNA in serum of colorectal cancer patients
复制标题
DOI：
10.3109/00365519709055283
复制
发表时间：
1997-11-01
影响因子：
2.1
通讯作者：
Swinkels, DW
中科院分区：
文献类型：
--
作者：
DeKok, JB;VanSolinge, WW;Swinkels, DW
此前曾在肺癌和头颈癌患者的血清和血浆中检测到循环肿瘤DNA。如果发现肿瘤是一种更普遍的现象，这些观察可能会潜在地为肿瘤疾病的诊断、预后和随访带来新的、特定的和非侵入性的工具。为了检测结直肠癌患者血清中是否也存在肿瘤DNA，我们选择了14例晚期结直肠癌患者。在7名患者中，使用K-ras基因第12或13密码子的点突变的突变特异性引物，在原发肿瘤中检测到K-ras突变。所有患者都进行了血清中突变DNA的分析。除了一名患者外，所有患者的血清中都检测到了与原发肿瘤中发现的K-ras突变相对应的肿瘤特异性点突变。7例原发肿瘤无K-ras突变的患者血清中均未检测到K-ras突变。这些结果可能有助于评估肿瘤患者的肿瘤负担。此外，手术或化疗后连续检测血清肿瘤DNA可作为复发疾病的肿瘤标志物。
Circulating tumour DNA has previously been detected in serum and plasma of patients with lung cancer and head and neck cancer. These observations could potentially lead to new, specific and non-invasive tools for diagnosis, prognosis and follow-up in neoplastic disease, if found to be a more general phenomenon. To test if tumour DNA is also present in serum of patients with colorectal cancer, we selected 14 colorectal cancer patients with advanced disease. In seven patients, K-ras mutations were detected in the primary tumour, using mutant-specific primers for point mutations in codon 12 or 13 of the K-ras gene. All patients were analysed for mutant DNA in serum. Tumour-specific point mutations, corresponding to the K-ras mutations found in the primary tumour were detected in the serum of all patients but one. No mutant K-ras could be detected in the serum of seven patients without K-ras mutations in the primary tumour. These results may be useful in assessing tumour burden in patients with neoplastic disease. Moreover, consecutive testing of serum tumour DNA after surgery or chemotherapy may be used as a tumour marker for recurrent disease.